XmAb942 Phase 1 data supports best-in-class profile with 74-day half-life enabling Q12W SC dosing and low immunogenicity. The XENITH-UC Phase 2b blinded interim around YE26 is the next major catalyst. XmAb412 FIH start in 3Q26 adds pipeline optionality. Monitor for partnership interest given precedent valuations shown ($1.5B-$10B+).
XNCR drugs
XNCR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $12.85entry
- T+1 · 7mo ago +1.25%α −0.14% · $13.01
- T+5 · 6mo ago −0.47%α −2.45% · $12.79
- T+20 · 6mo ago −12.76%α −17.72% · $11.21
- T+60 · 4mo ago +67.24%α +64.50% · $21.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xencor reported final Phase 1 data for XmAb942, an anti-TL1A antibody for IBD, showing a terminal half-life of 74.1 days, favorable safety, and low immunogenicity (0% neutralizing antibodies at target dose). The company also presented preclinical data for XmAb412, a TL1A x IL23p19 bispecific, with predicted human half-life of 60-70 days. Enrollment in the Phase 2b XENITH-UC study remains on track with a blinded interim analysis expected around year-end 2026 and primary endpoint results in 2H27.
Key Facts
- XmAb942 Phase 1 estimated terminal half-life of 74.1 days from pooled single-dose cohorts
- 0% neutralizing antibodies (NAb+) at XENITH-UC target dose regimen; 25% ADA+ at target dose
- 86% of patients predicted to achieve >99% TL1A inhibition at induction (Week 12) per QSP model
- 90% of patients predicted to achieve >90% TL1A inhibition at maintenance (Week 52) with Q12W SC dosing
- No serious or severe TEAEs; TEAE rates similar between XmAb942 (75%) and placebo (69%)
- XmAb412 predicted human half-life of 60-70 days; NHP half-life >20 days
- XmAb412 FIH study expected to begin 3Q26
- XENITH-UC Phase 2b enrolling ~220 patients; blinded interim analysis ~YE26, primary endpoint 2H27
- Cash position ~$611M as of Dec 31, 2025
Financial Impact
No financial data reported; clinical-stage biotech with ~$611M cash position
Risk Factors
- Phase 2b XENITH-UC results may not replicate Phase 1 PK/PD predictions
- Competitive landscape includes multiple first-gen anti-TL1A programs (afimkibart, tulisokibart, duvakitug) in Phase 3
- ADA incidence of 57% across all doses could impact long-term efficacy if neutralizing antibodies emerge
- No revenue-generating products; dependent on pipeline success and partnerships
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000036 |
| Document: xncr-20260504xexx992.htm | 0001326732-26-000036 |
| Document: xncr-20260504.htm | 0001326732-26-000036 |
| Document: 0001326732-26-000036-index-headers.html | 0001326732-26-000036 |
| Document: 0001326732-26-000036-index.html | 0001326732-26-000036 |
| Document: 0001326732-26-000036.txt | 0001326732-26-000036 |
Track record
20 reports on XNCR
3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +49.10% at T+60 after the Aug 5, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
- Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers